[1] E. E. Graves, R. Weissleder, V. Ntziachristos, “Fluorescence molecular imaging of small animal tumor model,” Current Molecular Medicine 4, 419–430 (2004)

[2] D. R. Larson, W. R. Zipfel, R. M. Williams, S. W. Clark, M. P. Bruchez, F. W. Wise, W. W. Webb, “Water-soluble quantum dots for multiphoton fluorescence imaging in vivo,” Science 300, 1434–1436 (2003)

[3] X. H. Gao, Y. Y. Cui, R. M. Levenson, L. W. K. Chung, S. M. Nie, “In vivo cancer targeting and imaging with semiconductor quantum dots,” Nat. Biotechnol. 22, 969–976 (2004)

[4] S. Kim, Y. Y. Lim, E. G. Soltesz, A. M. D. Grand, J. Lee, A. Nakayama, J. A. Parker, T. Mihaljevic, R. Laurence, L. H. Cohn, M. G. Bawendi, J. V. Frangioni, “Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping,” Nat. Biotechnol. 22, 93–97 (2004)

[5] J. Czernin, M. E. Phelps, “Positron emission tomography scanning: Current and future applications,” Ann. Rev. Med. 53, 89–112 (2002)

[6] G. D. Luker, D. Piwnica-Worms, “Molecular imaging in vivo with PET and SPECT,” Acad. Radiol. 8, 4–14 (2001)

[7] P. A. Dayton, D. Pearson, J. Clark, S. Simon, P. A. Schumann, R. Zutshi, T. O. Matsunaga, K. W. Ferrara, “Ultrasonic analysis of peptide- and antibodytargeted microbubble contrast agents for molecular imaging of αvβ3-expressing cells,” Molecular Imaging 3, 125–134 (2004)

[8] J.-H. Lee, Y.-M. Huh, Y.-W. Jun, J.-W. Seo, J.-T. Jang, H.-T. Song, S. Kim, E.-J. Cho, H.-G. Yoon, J.- S. Suh, J. Cheon, “Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging,” Nat. Med. 13, 95–99 (2007)

[9] M. A. Funovics, B. Kapeller, C. Hoeller, H. S. Su, R. Kunstfeld, S. Puig, K. Macfelda, “MR imaging of the HER2/neu and 9.2.27 tumor antigens using immunospecific contrast agents,” Magn. Reson. Imaging 22, 843–850 (2004)

[10] I. H. El-Sayed, X. H. Huang, M. A. El-Sayed, “Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: Applications in oral cancer,” Nano Lett. 5, 829–834 (2005)

[11] S. A. Boppart, A. L. Oldenburg, C. Xu, D. L. Marks, “Optical probes and techniques for molecular contrast enhancement in coherence imaging,” J. Biomed. Opt. 10, 1–14 (2005)

[12] T. M. Lee, F. J. Toublan, S. Sitafalwalla, A. L. Oldenburg, K. S. Suslickm, S. A. Boppart, “Engineered microsphere contrast agents for optical coherence tomography,” Opt. Lett. 28, 1546–1548 (2003)

[13] A. L. Oldenburg, F. J. Toublan, K. S. Suslick, A. Wei, S. A. Boppart, “Magnetomotive contrast for in vivo optical coherence tomography,” Opt. Exp. 13, 6597–6614 (2005)

[14] C. Loo, A. Lowery, N. Halas, J. West, R. Drezek, “Immunotargeted nanoshells for integrated cancer imaging and therapy,” Nano Lett. 5, 709–711 (2005)

[15] N. Desai, V. Trieu, Z. W. Yao, L. Louie, S. Ci, A. Yang, C. Tao, T. De, B. Beals, D. Dykes, P. Noker, R. Yao, E. Labao, M. Hawkins, P. Soon- Shiong, “Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel,” Clin. Cancer Res. 12, 1317–1324 (2006)

[16] R. Weissleder, A. Bogdanov, E. A. Neuwelt, M. Papisov, “Long-circulating iron oxides for MR imaging,” Adv. Drug Delivery Rev. 16, 321–334 (1995)

[17] J. Sinek, H. Frieboes, X. Zheng, V. Cristini, “Twodimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles,” Biomedical Microdevices 6, 297–309 (2004)

[18] B. Schade, S. H. L. Lam, D. Cernea, V. Sanguin- Gendreau, R. D. Cardiff, B. L. Jung, M. Hallett, W. J. Muller, “Distinct ErbB-2–coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles,” Cancer Res. 67, 7579–7589 (2007)

[19] N. W. Shi Kam, M. O’Connell, J. A. Wisdom, H. Dai, “Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction,” Proc. Natl. Acad. Sci. U.S.A. 102, 11600–11605 (2005)

[20] S. J. DeNardo, G. L. DeNardo, L. A. Miers, A. Natarajan, A. R. Foreman, C. Gr¨uettner, G. N. Adamson, R. Ivkov, “Development of tumor targeting bioprobes (in-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy,” Clin. Cancer Res. 11, 7087–7092 (2005)

[21] P. Sharma, S. C. Brown, G. Walter, S. Santra, E. Scott, H. Ichikawa, Y. Fukumori, “Gdnanoparticulates: From magnetic resonance imaging to neutron capture therapy,” Adv. Powder Techn. 18, 663–698 (2007)

[22] N. Nasongkla, E. Bey, J. Ren, H. Ai, C. Khemtong, J. S. Guthi, S.-F. Chin, A. D. Sherry, D. A. Boothman, J. Gao, “Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems,” Nano Lett. 6, 2427–2430 (2006)

[23] X.-H. Peng, X. Qian X, H. Mao, A. Y. Wang, Z. Chen, S. Nie, D. M. Shin, “Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy,” Intl. J. Nanomedicine 3, 311–321 (2008)

[24] Y. X. J. Wang, S. M. Hussain, G. P. Krestin, “Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging,” European Radiology 11, 2319–2331 (2001)

[25] C. C. Berry, S. Wells, S. Charles, G. Aitchison, A. S. G. Curtis, “Cell response to dextran-derivatised iron oxide nanoparticles post internalization,” Biomaterials 25, 5405–5413 (2004)

[26] H. Lee, E. Lee, D. K. Kim, N. K. Jang, Y. Y. Jeong, S. Jon, “Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging,” J. Am. Chem. Soc. 128, 7383–7389 (2006)

[27] A. K. Gupta,M. Gupta, “Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications,” Biomaterials 26, 3995–4021 (2005)

[28] J. R. McCarthy, R. Weissleder, “Multifunctional magnetic nanoparticles for targeted imaging and therapy,” Adv. Drug Delivery Rev. 60, 1241–1251 (2008)

[29] D. Simberg, T. Duza, J. H. Park, M. Essler, J. Pilch, L. Zhang, A. M. Derfus, M. Yang, R. M. Hoffman, S. Bhatia, M. J. Sailor, E. Ruoslahti, “Biomimetic amplification of nanoparticle homing to tumors,” Proc. Nat. Acad. Sci. U.S.A. 104, 932–936 (2007)

[30] F. Ibraimi, D. Kriz, M. Lu, L.-O. Hansson, K. Kriz, “Rapid one-step whole blood C-reactive protein magnetic permeability immunoassay with monoclonal antibody conjugated nanoparticles as superparamagnetic labels and enhanced sedimentation,” Analytical and Bioanalytical Chem. 384, 651–657 (2006)

[31] C. Gr¨uttner, K. M¨uller, J. Teller, F. Westphal, A. Foreman, R. Ivkov, “Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy,” J. Magnetism and Magnetic Materials 311, 181–186 (2007)

[32] E. Okon, D. Pouliquen, P. Okon, Z. V. Kovaleva, T. P. Stepanova, S. G. Lavit, B. N. Kudryavtsev, P. Jallet, “Biodegradation of magnetite dextran nanoparticles in the rat: A histologic and biophysical study,” Laboratory Investigation 71, 895–903 (1994)

[33] H. Pardoe, W. Chua-Anusorn, T. G. St. Pierre, J. Dobson, “Detection limits for ferrimagnetic particle concentrations using magnetic resonance imaging based on proton transverse relaxation rate measurements,” Physics in Medicine and Biology 48, N89– N95 (2003)

[34] J. W. Park, K. Hong, D. B. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, U. B. Nielsen, J. D. Marks, D. Moore, D. Papahadjopoulos, C. C. Benz, “Anti-HER2 immunoliposomes enhanced efficacy attributable to targeted delivery,” Clin. Cancer Res. 8, 1172–1181 (2002)

[35] J. M. Perez, F. J. Simeone, Y. Saeki, L. Josephson, R. Weissleder, “Viral-induced self-assembly of magnetic nanoparticles allows the detection of viral particles in biological media,” J. Am. Chem. Soc. 125, 10192–10193 (2003)

[36] H. Tada, H. Higuchi, T. M. Wanatabe, N. Ohuchi, “In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice,” Cancer Res. 67, 1138–1144 (2007)

[37] M. B. Wilson, P. K. Nakane, “The covalent coupling of proteins to periodate-oxidized sephadex: A new approach to immunoadsorbent preparation,” J. Immunol. Methods 12, 171–181 (1976)

[38] J. M. C. Luk, A. A. Lindberg, “Rapid and sensitive detection of Salmonella (O: 6,7) by immunomagnetic monoclonal antibody-based assays,” J. Immunol. Methods 137, 1–8 (1991)

[39] L. X. Tiefenauer, G. K¨uhne, R. Y. Andres, “Antibody-magnetite nanoparticles: In vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging,” Bioconjugate Chem. 4, 347–352 (1993)

[40] F. Bonneaux, E. Dellacherie, P. Labrude, C. Vigneron, “Hemoglobin-dialdehyde dextran conjugates: Improvement of their oxygen-binding properties with anionic groups,” J. Protein Chem. 15, 461–465 (1996)

[41] S. M. Moghimi, A. C. Hunter, J. C. Murray, “Nanomedicine: Current status and future prospects,” FASEB J. 19, 311–330 (2005).